ArticleMaterials today. Bio2026

Biohybrid nanovesicle-mediated targeted delivery of HSP90 inhibitor for enhanced sorafenib therapy of hepatocellular carcinoma after radiofrequency ablation.

Angfeng Jiang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.